MCID: NRN004
MIFTS: 56

Neuroendocrine Tumor

Categories: Cancer diseases, Endocrine diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Neuroendocrine Tumor

MalaCards integrated aliases for Neuroendocrine Tumor:

Name: Neuroendocrine Tumor 12 77 54 15
Neuroendocrine Neoplasm 12 54 30 6 17
Neuroendocrine Tumors 56 45 74
Carcinoma, Neuroendocrine 74
Neuroendocrine Neoplasia 54

Classifications:



External Ids:

Disease Ontology 12 DOID:169
ICD9CM 36 209 209-209.99
MeSH 45 D018358
NCIt 51 C3809
ICD10 34 D3A.8

Summaries for Neuroendocrine Tumor

NIH Rare Diseases : 54 A neuroendocrine tumor (NET) is a rare type of tumor that arises from specialized body cells called neuroendocrine cells. These cells have traits of both nerve cells and hormone-producing cells, and release hormones into the blood in response to signals from the nervous system. Because a neuroendocrine tumor arises from cells that produce hormones, the tumor can also produce hormones. Neuroendocrine tumors can develop anywhere in the body, but most occur in the digestive tract, pancreas, rectum, lungs, or appendix. They can be non-cancerous (benign) or cancerous (malignant). They usually grow slowly over many years, but there are fast-growing forms. There are many types of neuroendocrine tumors, but most are classified as one of two main types:Carcinoid tumors - NETs that most commonly arise in the digestive tract, lungs, appendix or thymus. They can also grow in the lymph nodes, brain, bone, gonads (ovaries and testes) or skin. Pancreatic neuroendocrine tumors (also called islet cell tumors) - NETs that typically arise in the pancreas, although they can occur outside the pancreas. A pheochromocytoma is another, rarer type of NET that usually develops in the adrenal gland, but can also arise in other parts of the body. Signs and symptoms depend on the tumor's type, size and location; whether it produces hormones; and whether it has spread to other parts of the body (metastasized). NETs are typically described as functional or nonfunctional. Functional NETs produce a specific set of symptoms due to the production of excess hormones, while non-functional NETs generally do not cause specific symptoms. In many cases, a person has no symptoms until the tumor spreads to the liver and/or impairs the function of an organ or system. This can make NETs very hard to diagnose. The majority of NETs are not inherited and occur sporadically in people with no family history of NETs. However, some NETs are associated with a hereditary cancer or tumor syndrome such as multiple endocrine neoplasia type 1 (most commonly), Von Hippel-Lindau disease, tuberous sclerosis, or neurofibromatosis type 1 (NF1). Inheritance of each of these is autosomal dominant. Treatment of NETs depends on many factors such as the tumor's type, location, aggressiveness, and hormone-producing capabilities; as well as whether it has metastasized. Management options may include surveillance, surgery to remove the tumor and/or surrounding tissue, and various non-surgical therapies to shrink the tumor, stop it from growing, or manage symptoms.

MalaCards based summary : Neuroendocrine Tumor, also known as neuroendocrine neoplasm, is related to gastrointestinal neuroendocrine tumor and esophageal neuroendocrine tumor. An important gene associated with Neuroendocrine Tumor is SST (Somatostatin), and among its related pathways/superpathways are Neuroscience and Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Pancrelipase and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include brain, thyroid and skin, and related phenotypes are nervous system and no phenotypic analysis

Disease Ontology : 12 An endocrine gland cancer that has material basis in neuroendocrine cells.

Wikipedia : 77 Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous... more...

Related Diseases for Neuroendocrine Tumor

Diseases related to Neuroendocrine Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 444)
# Related Disease Score Top Affiliating Genes
1 gastrointestinal neuroendocrine tumor 33.9 CHGA SST SYP
2 esophageal neuroendocrine tumor 33.4 CHGA NCAM1 SYP
3 gastric neuroendocrine neoplasm 33.1 CHGA GAST SST
4 insulinoma 32.7 CHGA INSM1 MEN1 SST
5 goblet cell carcinoid 32.5 CHGA ENO2 GAST
6 gastrinoma 32.5 CHGA GAST MEN1 SST
7 glucagonoma 32.5 CHGA CHGB SST
8 von hippel-lindau syndrome 32.4 CHGA CHGB MEN1
9 vipoma 32.2 CHGA GAST NTS SST
10 insulinomatosis and diabetes mellitus 32.1 CHGA GAST SST
11 gastric gastrinoma 32.1 ENO2 GAST
12 duodenal somatostatinoma 31.9 CALCA ENO2 SST
13 adrenal carcinoma 31.8 ENO2 MEN1 SYP
14 duodenal gastrinoma 31.5 CCK CHGA ENO2 GAST MEN1 SST
15 pancreatic cancer 31.3 CCK GAST MEN1 NTS SST SSTR2
16 multiple endocrine neoplasia 31.2 CALCA CHGA MEN1
17 multiple endocrine neoplasia, type i 30.7 CHGA GAST MEN1 SST SYP
18 acromegaly 30.6 MEN1 SST SSTR2
19 pernicious anemia 30.5 GAST SST
20 paraganglioma 30.5 CHGA ENO2 SST SYP
21 atrophic gastritis 30.3 CHGA GAST SST
22 growth hormone secreting pituitary adenoma 30.2 SST SSTR2
23 horseshoe kidney 30.2 CHGA ENO2 SYP
24 autoimmune atrophic gastritis 30.2 CHGA GAST
25 olfactory neuroblastoma 30.1 CHGA ENO2 SSTR2 SYP
26 zollinger-ellison syndrome 30.0 CHGA GAST MEN1 NTS SST
27 benign ependymoma 30.0 ENO2 SYP
28 parathyroid adenoma 29.8 CALCA CHGA MEN1
29 ectopic cushing syndrome 29.8 MEN1 SST SYP
30 hemangioma 29.8 CHGA ENO2 SYP
31 pituitary carcinoma 29.8 CHGA SST
32 pulmonary large cell neuroendocrine carcinoma 29.8 CHGA ENO2 SYP
33 hyperparathyroidism 29.7 CALCA CHGA GAST MEN1
34 somatostatinoma 29.7 CALCA CHGA ENO2 SST
35 duodenal ulcer 29.6 CCK GAST SST
36 carcinoid syndrome 29.6 CALCA CHGA ENO2 MEN1 NTS SST
37 ependymoma 29.5 ENO2 MEN1 MKI67 SYP
38 diarrhea 29.5 CCK GAST SST
39 gastrointestinal stromal tumor 29.3 CHGA ENO2 MEN1 MKI67 NCAM1 SYP
40 meningioma, familial 29.3 ENO2 MEN1 MKI67 SST SSTR2 SYP
41 ganglioneuroma 29.3 CHGA ENO2 NCAM1 SYP
42 gallbladder small cell carcinoma 29.3 CHGA ENO2 NCAM1 SYP
43 large cell neuroendocrine carcinoma 29.0 ASCL1 CHGA ENO2 NCAM1 SYP
44 merkel cell carcinoma 28.9 CHGA ENO2 NCAM1 SST SYP
45 small cell carcinoma 28.8 CALCA CHGA ENO2 NCAM1 SYP
46 carcinoid tumors, intestinal 28.7 CHGA CHGB ENO2 MEN1 SST SSTR2
47 thyroid carcinoma, familial medullary 28.6 CALCA CCK CHGA CHGB ENO2 GAST
48 pheochromocytoma 27.9 ASCL1 CALCA CHGA CHGB ENO2 MEN1
49 small cell cancer of the lung 27.8 ASCL1 CALCA CHGA ENO2 GAST INSM1
50 pancreatic neuroendocrine tumor 12.6

Graphical network of the top 20 diseases related to Neuroendocrine Tumor:



Diseases related to Neuroendocrine Tumor

Symptoms & Phenotypes for Neuroendocrine Tumor

MGI Mouse Phenotypes related to Neuroendocrine Tumor:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.73 ASCL1 CCK CHGA CHGB ENO2 INSM1
2 no phenotypic analysis MP:0003012 9.23 ASCL1 CCK CHGA CHGB INSM1 MKI67

Drugs & Therapeutics for Neuroendocrine Tumor

Drugs for Neuroendocrine Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 733)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 53608-75-6
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
3
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
4
Vindesine Approved, Investigational Phase 4 53643-48-4, 59917-39-4 40839
5
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4342-03-4 5351166
6
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
7
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 38916-34-6, 51110-01-1 53481605
8
lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 108736-35-2
9
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
10
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 46835353 5284616 6436030
11
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 70789204 6442177
12
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 22916-47-8 4189
13
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
14
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
15
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 83150-76-9 6400441 383414
16
Sargramostim Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 123774-72-1, 83869-56-1
17
Pembrolizumab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 1374853-91-4
18
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
19
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 946414-94-4
20
Ipilimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 477202-00-9
21
Vemurafenib Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 918504-65-1 23252090 42611257
22
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
23
Palbociclib Approved, Investigational Phase 4,Phase 1,Phase 2 571190-30-2 5005498 11431660 5330286
24
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 110942-02-4, 85898-30-2
25
Etanercept Approved, Investigational Phase 4 185243-69-0
26
Doxazosin Approved Phase 4,Phase 3 74191-85-8 3157
27
Phenoxybenzamine Approved Phase 4,Phase 3 59-96-1 4768
28
Aminolevulinic acid Approved Phase 4 106-60-5 137
29
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99011-02-6 57469
30
Pasireotide Approved Phase 4,Phase 3,Phase 2,Phase 1 396091-73-9 9941444
31
Dabrafenib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1195765-45-7 44462760 44516822
32
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
33
Gefitinib Approved, Investigational Phase 4,Phase 2,Not Applicable 184475-35-2 123631
34
Dasatinib Approved, Investigational Phase 4,Phase 1,Phase 2 302962-49-8 3062316
35
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 149647-78-9 5311
36
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
37
Crizotinib Approved Phase 4,Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
38
Ceritinib Approved Phase 4,Phase 2,Phase 1 1032900-25-6
39
Olaparib Approved Phase 4 763113-22-0 23725625
40
Lactitol Investigational Phase 4,Phase 1,Phase 2 585-88-6, 585-86-4 493591
41
Lapatinib Approved March 2007, Investigational Phase 4,Phase 2,Early Phase 1 231277-92-2, 388082-78-8 208908 9941095
42 pancreatin Phase 4,Phase 1,Phase 2,Not Applicable
43 Fluorodeoxyglucose F18 Phase 4,Phase 2,Phase 1,Not Applicable
44 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
45 Gentamicins Phase 4,Not Applicable
46 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
47 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
48 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
49 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2731)
# Name Status NCT ID Phase Drugs
1 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Unknown status NCT02759718 Phase 4
2 Nonfunctional Pancreatic NET and PET Imaging Unknown status NCT02621541 Phase 4
3 Radiolabeled Molecules for Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
4 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Unknown status NCT02379754 Phase 4 Gentamicins
5 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
6 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
7 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
8 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients Completed NCT02075606 Phase 4 lanreotide acetate
9 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Completed NCT01525550 Phase 4 sunitinib
10 An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1) Completed NCT01595009 Phase 4 Everolimus (RAD001)
11 Somatuline Autogel Preference and Health Economy Study Completed NCT00681187 Phase 4 lanreotide (Autogel formulation)
12 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
13 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
14 Phenoxybenzamine Versus Doxazosin in PCC Patients Completed NCT01379898 Phase 4 Phenoxybenzamine;Doxazosin
15 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
16 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
17 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Completed NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
18 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
19 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
20 A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide Recruiting NCT03289741 Phase 4 Octreotide;LAR Lanreotide
21 Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET Recruiting NCT03083210 Phase 4 Lanreotide
22 Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. Recruiting NCT01789281 Phase 4 Everolimus;Sandostatin LAR Depot
23 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
24 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4 GM-CSF
25 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
26 Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) Recruiting NCT03715205 Phase 4 Pembrolizumab
27 Dabrafenib and/or Trametinib Rollover Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
28 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
29 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Active, not recruiting NCT02842749 Phase 4 everolimus
30 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Active, not recruiting NCT02626065 Phase 4 Nivolumab
31 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4 Ipilimumab
32 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4 Zelboraf
33 Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies Not yet recruiting NCT03673332 Phase 4 immune-checkpoint inhibitors therapies
34 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4 Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care
35 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
36 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
37 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
38 Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut Unknown status NCT00171873 Phase 3 Octreotide LAR (Long-acting release);Placebo
39 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
40 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
41 Neoadjuvant L19IL2/L19TNF- Pivotal Study Unknown status NCT02938299 Phase 3 L19IL2 + L19TNF
42 Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients Unknown status NCT01861938 Phase 2, Phase 3
43 Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients Unknown status NCT01729663 Phase 2, Phase 3 interferon alpha 2b
44 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
45 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
46 Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC Unknown status NCT00779714 Phase 3 DTIC (dacarbazine);paclitaxel + cisplatin;treosulfan + cytarabine
47 Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon Unknown status NCT00226408 Phase 3 Interferon-alpha-2b
48 Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma Unknown status NCT00002767 Phase 3
49 High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00002763 Phase 3
50 Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Unknown status NCT00039234 Phase 3 histamine dihydrochloride

Search NIH Clinical Center for Neuroendocrine Tumor

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: neuroendocrine tumors

Genetic Tests for Neuroendocrine Tumor

Genetic tests related to Neuroendocrine Tumor:

# Genetic test Affiliating Genes
1 Neuroendocrine Neoplasm 30

Anatomical Context for Neuroendocrine Tumor

MalaCards organs/tissues related to Neuroendocrine Tumor:

42
Brain, Thyroid, Skin, Lymph Node, Pancreas, Kidney, T Cells

Publications for Neuroendocrine Tumor

Articles related to Neuroendocrine Tumor:

(show top 50) (show all 1370)
# Title Authors Year
1
Value of Texture Analysis of Intravoxel Incoherent Motion Parameters in Differential Diagnosis of Pancreatic Neuroendocrine Tumor and Pancreatic Adenocarcinoma. ( 30961774 )
2019
2
Analysis of pituitary adenoma expression patterns suggests a potential role for the NeuroD1 transcription factor in neuroendocrine tumor-targeting therapies. ( 30719226 )
2019
3
Gastric Neuroendocrine Tumor and Duodenal Gastrinoma With Chronic Autoimmune Atrophic Gastritis. ( 30531243 )
2019
4
Subacute Combined Degeneration, Pernicious Anemia and Gastric Neuroendocrine Tumor Occured Simultaneously Caused by Autoimmune Gastritis. ( 30740042 )
2019
5
Primary testicular neuroendocrine tumor with azoospermia: Extending indications for testicle-sparing surgery. ( 30705829 )
2019
6
Prevalence of hitherto unknown brain meningioma detected on 68Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of 177Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors. ( 31040748 )
2019
7
Y90 Clinical Data Update: Cholangiocarcinoma, Neuroendocrine Tumor, Melanoma, and Breast Cancer Metastatic Disease. ( 31079715 )
2019
8
A case report on metastatic ileal neuroendocrine neoplasm to the breast masquerading as primary breast cancer: A diagnostic challenge and management dilemma. ( 31008928 )
2019
9
A novel case of TIF1 gamma autoantibody positive dermatomyositis associated with a non-functional pancreatic neuroendocrine tumor. ( 30982303 )
2019
10
Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT. ( 30688738 )
2019
11
Ectopic corticotropin-releasing hormone syndrome caused by pancreatic neuroendocrine tumor localized by 68Ga-DOTATATE PET/CT. ( 30519868 )
2019
12
Dual Imaging With 68Ga-DOTATOC and 18F-FDG PET for Planning and Follow-up of PRRT in Combination With Temozolomide Treatment in a Patient With a Metastatic Neuroendocrine Tumor. ( 30829861 )
2019
13
Abstracts of the 16th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. ( 30844802 )
2019
14
Robotic Complete Mesocolic Excision for Right-Sided Neuroendocrine Tumor. ( 30844975 )
2019
15
Primary Renal Well-differentiated Neuroendocrine Tumor (Carcinoid): Next- Generation Sequencing Study of 11 Cases. ( 30851202 )
2019
16
Three trocars laparoscopic right ileocolectomy for advanced small bowel neuroendocrine tumor. ( 30851916 )
2019
17
Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately. ( 30863939 )
2019
18
The Search for an Alternative to [68Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of 18F-labeled Somatostatin Analog Development. ( 30867834 )
2019
19
A well-differentiated neuroendocrine tumor (Grade I) arising in a tailgut cyst. ( 30880789 )
2019
20
Pancreatic neuroendocrine tumor: prediction of the tumor grade using magnetic resonance imaging findings and texture analysis with 3-T magnetic resonance. ( 30881119 )
2019
21
Clinicopathological features and prognosis factors for survival in elderly patients with pancreatic neuroendocrine tumor: A STROBE-compliant article. ( 30882623 )
2019
22
Preoperative diagnosis of well-differentiated neuroendocrine tumor in common hepatic duct by brush cytology: A case report. ( 30884200 )
2019
23
Neuroendocrine tumor of the appendix: Twelve years of results from a single institution. ( 30892667 )
2019
24
Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. ( 30903344 )
2019
25
PITX2 Expression in Non-functional Pituitary Neuroendocrine Tumor with Cavernous Sinus Invasion. ( 30903445 )
2019
26
Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model. ( 30926632 )
2019
27
Evaluating the ACS NSQIP Risk Calculator in Primary Pancreatic Neuroendocrine Tumor: Results from the US Neuroendocrine Tumor Study Group. ( 30941685 )
2019
28
Role of everolimus in the treatment of advanced neuroendocrine tumor: a meta-analysis of randomized trials. ( 30941993 )
2019
29
Periprocedural Management of Patients Undergoing Liver Resection or Embolotherapy for Neuroendocrine Tumor Metastases. ( 30946246 )
2019
30
Neuroendocrine tumor of the appendix-a case report and review of the literature. ( 30949336 )
2019
31
Mixed Adenocarcinomatous and Neuroendocrine Tumor of the Urinary Bladder With Concomitant Carcinoma In Situ: A Case Report With a Comprehensive Immunohistochemical Analysis and Review of the Literature. ( 30955388 )
2019
32
Signet ring: A rare morphology of metastatic neuroendocrine tumor. ( 30971572 )
2019
33
Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review. ( 30972265 )
2019
34
Endoscopic Resection of a Rectal Neuroendocrine Tumor: Hybrid Endoscopic Submucosal Dissection. ( 30976620 )
2019
35
Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor. ( 30986806 )
2019
36
Minimally invasive versus open distal pancreatectomy for pancreatic neuroendocrine tumors: An analysis from the U.S. neuroendocrine tumor study group. ( 31001868 )
2019
37
Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group. ( 31004295 )
2019
38
A rare rarity: Neuroendocrine tumor of the esophagus. ( 31014519 )
2019
39
Additional value of a dynamic contrast-enhanced study for detection of a small neuroendocrine tumor of the rectum on magnetic resonance imaging. ( 31019350 )
2019
40
An Uncommon Case of Ectopic Adrenocorticotropic Hormone Syndrome from a Pancreatic Neuroendocrine Tumor. ( 31019854 )
2019
41
Robotic Central Pancreatectomy for Well-Differentiated Neuroendocrine Tumor: Parenchymal-Sparing Procedure. ( 31020502 )
2019
42
Diagnostic and Therapeutic Uptake of Intrathyroid Metastasis of Midgut Neuroendocrine Tumor on 68Ga-DOTANOC PET/CT and 177Lu-DOTATATE Imaging. ( 31021912 )
2019
43
Liver Transplantation for High-Grade Primary Hepatic Neuroendocrine Tumor with Diffuse Liver Metastasis. ( 31028538 )
2019
44
Efficacy of Perioperative Endoscopic Naso-Pancreatic Drainage in Laparoscopic Enucleation of Pancreatic Nonfunctioning Neuroendocrine Tumor. ( 30819314 )
2019
45
Combination of 5-Fluorouracil With Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression and Radioligand Binding in Neuroendocrine Tumor Cells in Vitro. ( 30796167 )
2019
46
A Case of Streptozocin Monotherapy for Unresectable Duodenal Neuroendocrine Tumor G2. ( 30792640 )
2019
47
Safety and Efficacy of Combined Peptide Receptor Radionuclide Therapy and Liver Selective Internal Radiation Therapy in a Patient With Metastatic Neuroendocrine Tumor. ( 30789395 )
2019
48
C-reactive protein may be a prognostic factor for the whole gastroenteropancreatic neuroendocrine tumor group. ( 30788040 )
2019
49
Large Cell Neuroendocrine Tumor Size >3 cm Negatively Impacts Long-Term Outcomes After R0 Resection. ( 30783763 )
2019
50
The Impact of Repeating Endosonography with Confocal Endomicroscopy for the Diagnosis of Cystic Neuroendocrine Tumor. ( 30755806 )
2019

Variations for Neuroendocrine Tumor

ClinVar genetic disease variations for Neuroendocrine Tumor:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CDKN1B NM_004064.4(CDKN1B): c.334delA (p.Ser112Alafs) deletion Likely pathogenic rs797044483 GRCh37 Chromosome 12, 12871107: 12871107
2 CDKN1B NM_004064.4(CDKN1B): c.334delA (p.Ser112Alafs) deletion Likely pathogenic rs797044483 GRCh38 Chromosome 12, 12718173: 12718173
3 CDKN1B NM_004064.4(CDKN1B): c.279_280insT (p.Pro94Serfs) insertion Likely pathogenic rs797044482 GRCh37 Chromosome 12, 12871052: 12871053
4 CDKN1B NM_004064.4(CDKN1B): c.279_280insT (p.Pro94Serfs) insertion Likely pathogenic rs797044482 GRCh38 Chromosome 12, 12718118: 12718119
5 CDKN1B NM_004064.4(CDKN1B): c.127delCinsTAA (p.Arg43Terfs) indel Likely pathogenic rs797044481 GRCh38 Chromosome 12, 12717966: 12717966
6 CDKN1B NM_004064.4(CDKN1B): c.127delCinsTAA (p.Arg43Terfs) indel Likely pathogenic rs797044481 GRCh37 Chromosome 12, 12870900: 12870900

Cosmic variations for Neuroendocrine Tumor:

9 (show top 50) (show all 58)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM14283 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.491A>G p.Q164R 3:10149814-10149814 0
2 COSM17662 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.492G>T p.Q164H 3:10149815-10149815 0
3 COSM18097 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.482G>A p.R161Q 3:10149805-10149805 0
4 COSM144972 VHL adrenal gland,NS,pheochromocytoma,benign c.245G>T p.R82L 3:10142092-10142092 0
5 COSM14321 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.227T>A p.F76Y 3:10142074-10142074 0
6 COSM144971 VHL adrenal gland,NS,pheochromocytoma,benign c.244C>G p.R82G 3:10142091-10142091 0
7 COSM6444479 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.260T>C p.V87A 3:10142107-10142107 0
8 COSM144975 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.475A>G p.K159E 3:10149798-10149798 0
9 COSM100047 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.389T>G p.V130G 3:10146562-10146562 0
10 COSM14311 VHL adrenal gland,NS,pheochromocytoma,benign c.499C>T p.R167W 3:10149822-10149822 0
11 COSM17982 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.496G>T p.V166F 3:10149819-10149819 0
12 COSM236660 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.250G>C p.V84L 3:10142097-10142097 0
13 COSM17988 VHL adrenal gland,NS,pheochromocytoma,benign c.341-1G>T p.? 3:10146513-10146513 0
14 COSM43931 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.523C>A p.R175S 17:7675089-7675089 0
15 COSM11286 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.1015G>T p.E339* 17:7670694-7670694 0
16 COSM10801 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.404G>A p.C135Y 17:7675208-7675208 0
17 COSM10659 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.817C>T p.R273C 17:7673803-7673803 0
18 COSM11071 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.1009C>T p.R337C 17:7670700-7670700 0
19 COSM44175 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.644G>C p.S215T 17:7674887-7674887 0
20 COSM966 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.1900T>C p.C634R 10:43114500-43114500 0
21 COSM965 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.2753T>C p.M918T 10:43121968-43121968 0
22 COSM220089 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1885G>A p.Q616fs*4 17:31225134-31225134 0
23 COSM329092 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1721+3A>T p.A548fs*13 17:31221932-31221932 0
24 COSM30670 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7646C>G p.S2549* 17:31356490-31356490 0
25 COSM329090 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.226G>T p.E76* 17:31159031-31159031 0
26 COSM5885098 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.5665G>T p.E1889* 17:31330351-31330351 0
27 COSM329093 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1722-1G>A p.? 17:31223443-31223443 0
28 COSM330587 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.205-1G>C p.R69Xfs*7 17:31159009-31159009 0
29 COSM327926 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.3158C>A p.S1053* 17:31230886-31230886 0
30 COSM327927 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7582C>T p.Q2528* 17:31352381-31352381 0
31 COSM33676 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.6855C>A p.Y2285* 17:31338739-31338739 0
32 COSM3402726 NF1 adrenal gland,NS,pheochromocytoma,benign c.1307C>A p.S436* 17:31206286-31206286 0
33 COSM1710108 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7300C>T p.Q2434* 17:31349230-31349230 0
34 COSM330588 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.2409+1G>A p.A776_Q803del 17:31227607-31227607 0
35 COSM329089 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1466A>G p.Y489C 17:31214524-31214524 0
36 COSM707 MET adrenal gland,adrenal gland,pheochromocytoma,benign c.3029C>T p.T1010I 7:116771936-116771936 0
37 COSM5967149 MET adrenal gland,adrenal gland,pheochromocytoma,benign c.607T>A p.S203T 7:116699691-116699691 0
38 COSM5946188 MET adrenal gland,adrenal gland,pheochromocytoma,benign c.352A>T p.M118L 7:116699436-116699436 0
39 COSM4445248 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.1132G>T p.E378* 11:64805688-64805688 0
40 COSM4445249 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.808C>A p.L270M 11:64807195-64807195 0
41 COSM4445247 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.812G>C p.G271A 11:64807191-64807191 0
42 COSM4445246 MED12 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.4857G>T p.K1619N 23:71134842-71134842 0
43 COSM499 HRAS adrenal gland,adrenal gland,pheochromocytoma,benign c.182A>G p.Q61R 11:533874-533874 0
44 COSM496 HRAS adrenal gland,adrenal gland,pheochromocytoma,benign c.181C>A p.Q61K 11:533875-533875 0
45 COSM486 HRAS adrenal gland,adrenal gland,pheochromocytoma,benign c.37G>C p.G13R 11:534286-534286 0
46 COSM1732355 H3F3A adrenal gland,adrenal gland,pheochromocytoma,benign c.103G>T p.G35W 1:226064454-226064454 0
47 COSM19176 FGFR1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1638C>A p.N546K 8:38417331-38417331 0
48 COSM6188660 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1592C>T p.P531L 2:46380264-46380264 0
49 COSM6476262 EPAS1 adrenal gland,NS,pheochromocytoma,benign c.1601C>T p.P534L 2:46380273-46380273 0
50 COSM6196613 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1589C>A p.A530E 2:46380261-46380261 0

Expression for Neuroendocrine Tumor

Search GEO for disease gene expression data for Neuroendocrine Tumor.

Pathways for Neuroendocrine Tumor

Pathways related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.56 CALCA ENO2 MKI67 NCAM1 SYP
2 11.23 ASCL1 NCAM1 SYP
3 9.8 CCK GAST

GO Terms for Neuroendocrine Tumor

Cellular components related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 CALCA CCK CHGA CHGB ENO2 GAST
2 secretory granule GO:0030141 9.5 CHGA CHGB SCG2
3 extracellular region GO:0005576 9.28 CALCA CCK CHGA CHGB GAST NCAM1
4 neuronal cell body GO:0043025 9.26 ASCL1 CCK ENO2 SST
5 terminal bouton GO:0043195 9.16 CCK SYP

Biological processes related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.88 CALCA CCK GAST NTS SST SSTR2
2 cellular protein metabolic process GO:0044267 9.56 CALCA CHGB MEN1 SCG2
3 positive regulation of neural precursor cell proliferation GO:2000179 9.43 ASCL1 INSM1
4 sympathetic ganglion development GO:0061549 9.37 ASCL1 INSM1
5 type B pancreatic cell differentiation GO:0003309 9.32 INSM1 MEN1
6 regulation of signaling receptor activity GO:0010469 9.17 CALCA CCK CHGB GAST NTS SCG2
7 noradrenergic neuron development GO:0003358 9.16 ASCL1 INSM1
8 adrenal chromaffin cell differentiation GO:0061104 8.96 ASCL1 INSM1

Molecular functions related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.02 CALCA CCK CHGB GAST SST

Sources for Neuroendocrine Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....